Can Migraine Care Be Reliably Measured? - Summary - MDSpire

Can Migraine Care Be Reliably Measured?

ACP review finds existing metrics inadequate and identifies data gaps that limit performance measurement.

  • By

  • Andrea Surnit

  • April 20, 2026

  • 3 min

Share

Objective:

To determine the suitability of existing performance measures for migraine treatment and assess the feasibility of recommending a core performance measure, while also identifying gaps and evaluating guideline-based recommendations.

Key Findings:
  • No suitable core performance measure for migraine care was identified.
  • Only one existing measure related to imaging overuse was found, but it was not supported due to lack of testing and outdated guidelines.
  • Guideline-recommended treatment measures were deemed infeasible due to poor data capture in electronic health records, particularly for over-the-counter medications.
Interpretation:

Current limitations in migraine measurement reflect challenges in data capture and documentation rather than deficiencies in care quality.

Limitations:
  • Inadequate data capture for over-the-counter medications.
  • Lack of testing for existing performance measures.
  • Variability in documentation practices affecting reliability.
Conclusion:

The ACP does not recommend a core performance measure for migraine treatment, emphasizing the need for improved measurement strategies.

Original Source(s)

Can Migraine Care Be Reliably Measured?

  • by Andrea Surnit

  • April 20, 2026

Related Content

Do Head Hits Shift the Gut Microbiome?

A small observational study in collegiate football players found microbiome associations after nonconcussive head impacts, though findings were limited by severe underpowering and high attrition

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.